Related Experiment Videos
Thrombolytic therapy in myocardial infarction
Annals of the Academy of Medicine, Singapore
|January 1, 1990
Summary
Streptokinase administration for myocardial infarction significantly reduces mortality by 18% and improves survival rates. Further research is needed for more potent thrombolytic drugs with fewer side effects.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Streptokinase, reintroduced in 1979, revolutionized myocardial infarction treatment.
- Thrombolytic therapy aims to recanalize occluded coronary arteries post-infarction.
Purpose of the Study:
- To review the efficacy and safety of streptokinase and recombinant tissue plasminogen activator (rt-PA) in myocardial infarction.
- To discuss complications and future directions in thrombolytic therapy.
Main Methods:
- Review of clinical studies including GISSI and ISIS-2.
- Comparison of streptokinase with rt-PA regarding recanalization, survival, and left ventricular function.
Main Results:
- Intravenous streptokinase showed an 18% mortality reduction (GISSI study).
- Aspirin addition improved survival (ISIS-2 study).
- rt-PA achieved higher patency rates and improved survival compared to streptokinase.
Conclusions:
- Thrombolytic therapy, including streptokinase and rt-PA, improves survival and left ventricular function in myocardial infarction.
- Complications include intracranial hemorrhage and bleeding; reinfarction risk necessitates ischemia assessment.
- Development of more effective and safer thrombolytic agents is ongoing.